Faiez Zannad

Summary

Affiliation: CHU de Nancy
Country: France

Publications

  1. ncbi The challenge of acute decompensated heart failure
    Faiez Zannad
    INSERM, Centre d Investigation Clinique CIC INSERM CHU, Hopital Jeanne d Arc, 54200, Dommartin les Toul, Nancy, France
    Heart Fail Rev 11:135-9. 2006
  2. ncbi Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, France
    Eur Heart J 33:2782-95. 2012
  3. ncbi Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and
    Faiez Zannad
    centre d investigation clinique, Institut Lorrain du Coeuret des Vaisseaux, CHU Brabois, Vandoeuvre, France
    Eur J Prev Cardiol 19:1454-64. 2012
  4. ncbi Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Hopital Jeanne d Arc, 54200 Toul, Nancy, France
    Eur Heart J 33:1049-57. 2012
  5. ncbi Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques
    Faiez Zannad
    Centre for Clinical Investigation, Institut Lorrain du Coeur et des Vaisseaux, CHU Brabois, 54500 Vandoeuvre, France
    Fundam Clin Pharmacol 26:163-74. 2012
  6. ncbi Nutrition, environment and cardiovascular health (NESCAV): protocol of an inter-regional cross-sectional study
    Ala a Alkerwi
    Centre de Recherche Public Santé, Centre d Etudes en Santé, Grand Duchy of Luxembourg
    BMC Public Health 10:698. 2010
  7. ncbi Cardiovascular high-risk patients--treat to protect, but whom?
    Faiez Zannad
    Hypertension and Heart Failure Unit, INSERM Clinical Investigation Centre, Nancy, France
    Medscape J Med 10:S2. 2008
  8. ncbi Implications of the ADVANCE study for clinical practice
    Faiez Zannad
    INSERM, CIC 9501 and U684, CHU Nancy, France
    J Hypertens Suppl 26:S29-32. 2008
  9. ncbi Managing hypertension: a question of STRATHE
    F Zannad
    Department of Cardiovascular Disease, Clinical Investigation Center INSERM CHU, University Henri Poincare, Nancy, France
    J Hum Hypertens 19:S3-7. 2005
  10. ncbi Extracellular matrix fibrotic markers in heart failure
    Faiez Zannad
    Hypertension and Heart Failure Unit, Department of Cardiology, Hopital Brabois, CHU de Nancy, Nancy, F 54000, France
    Heart Fail Rev 15:319-29. 2010

Detail Information

Publications123 found, 100 shown here

  1. ncbi The challenge of acute decompensated heart failure
    Faiez Zannad
    INSERM, Centre d Investigation Clinique CIC INSERM CHU, Hopital Jeanne d Arc, 54200, Dommartin les Toul, Nancy, France
    Heart Fail Rev 11:135-9. 2006
    ..A combined endpoint assessing survival and rehospitalisation rates is becoming increasingly popular for acute therapies. Specific trials may also need to be designed according to the time of access to the patient...
  2. ncbi Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, France
    Eur Heart J 33:2782-95. 2012
    ..When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF-REF...
  3. ncbi Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and
    Faiez Zannad
    centre d investigation clinique, Institut Lorrain du Coeuret des Vaisseaux, CHU Brabois, Vandoeuvre, France
    Eur J Prev Cardiol 19:1454-64. 2012
    ..In conclusion, opportunities exist to increase guideline implementation in the primary care setting, with potential benefits for both the general population and healthcare resources...
  4. ncbi Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Hopital Jeanne d Arc, 54200 Toul, Nancy, France
    Eur Heart J 33:1049-57. 2012
    ....
  5. ncbi Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques
    Faiez Zannad
    Centre for Clinical Investigation, Institut Lorrain du Coeur et des Vaisseaux, CHU Brabois, 54500 Vandoeuvre, France
    Fundam Clin Pharmacol 26:163-74. 2012
    ..However, their additional value above and beyond classical risk factors has yet to be determined for risk-guided therapy in CVD prevention...
  6. ncbi Nutrition, environment and cardiovascular health (NESCAV): protocol of an inter-regional cross-sectional study
    Ala a Alkerwi
    Centre de Recherche Public Santé, Centre d Etudes en Santé, Grand Duchy of Luxembourg
    BMC Public Health 10:698. 2010
    ....
  7. ncbi Cardiovascular high-risk patients--treat to protect, but whom?
    Faiez Zannad
    Hypertension and Heart Failure Unit, INSERM Clinical Investigation Centre, Nancy, France
    Medscape J Med 10:S2. 2008
    ....
  8. ncbi Implications of the ADVANCE study for clinical practice
    Faiez Zannad
    INSERM, CIC 9501 and U684, CHU Nancy, France
    J Hypertens Suppl 26:S29-32. 2008
    ....
  9. ncbi Managing hypertension: a question of STRATHE
    F Zannad
    Department of Cardiovascular Disease, Clinical Investigation Center INSERM CHU, University Henri Poincare, Nancy, France
    J Hum Hypertens 19:S3-7. 2005
    ..The results of STRATHE provide further support for an antihypertensive management strategy involving the low-dose combination of perindopril (2 mg) and indapamide (0.625 mg)...
  10. ncbi Extracellular matrix fibrotic markers in heart failure
    Faiez Zannad
    Hypertension and Heart Failure Unit, Department of Cardiology, Hopital Brabois, CHU de Nancy, Nancy, F 54000, France
    Heart Fail Rev 15:319-29. 2010
    ..Biomarkers may be selectively influenced by pharmacological agents...
  11. ncbi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  12. ncbi Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study
    Faiez Zannad
    Department of Cardiology, University Hospital of Nancy, France
    Eur J Heart Fail 8:697-705. 2006
    ..Observational data may improve disease management and guide the design of clinical trials...
  13. ncbi Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)
    Faiez Zannad
    INSERM, Centre d Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University, Nancy, France
    Eur J Heart Fail 12:617-22. 2010
    ..CONCLUSION: The study will be complete when approximately 813 subjects experience a primary endpoint. Clinical Trials.gov. NCT00232180...
  14. ncbi Heart failure burden and therapy
    Faiez Zannad
    Departement of cardiology, INSERM, CIC9501 and U961, CHU Nancy, Hypertension and Heart Failure Unit, CHU, Nancy Universite, 54500 Vandoeuvre les Nancy, France
    Europace 11:v1-9. 2009
    ....
  15. ncbi Implications of the ADVANCE study for clinical practice
    Faiez Zannad
    INSERM, CIC 9501 et U684, CHU Nancy, France
    J Hypertens 26:S31-4. 2008
    ....
  16. ncbi Profile of patients with type 2 diabetes in France and Italy
    Faiez Zannad
    INSERM, CIC 9501, INSERM, U684, CHU Nancy and Nancy University, Nancy, France
    J Hypertens Suppl 26:S3-6. 2008
    ..Greater adherence to therapeutic targets recommended in guidelines will ensure that greater proportions of patients attain these treatment goals thereby reducing diabetes-related morbidity and mortality...
  17. ncbi Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies
    F Zannad
    Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, Centre d Investigations Cliniques INSERM CHU, INSERM U684, Nancy, France
    Kidney Int 70:1318-24. 2006
    ..These trends may have become statistically significant had the sample size been larger, and these findings warrant further study...
  18. ncbi [Effects of calcium antagonists on atherosclerosis progression and intima media thickness]
    F Zannad
    Centre d Investigations Cliniques INSERM CHU, Nancy, France
    Drugs 59:39-46. 2000
    ..A larger trial with a longer follow-up period should be performed in order to confirm the promising results of PREVENT...
  19. ncbi Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition
    Faiez Zannad
    Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, Centre d Investigations Cliniques INSERM CHU, INSERM U684, Hopital Jeanne d Arc, 54200 Dommartin Les Toul, Nancy, France
    Eur Heart J 29:413-21. 2008
    ..This paper examines issues related to defining heart failure events in cardiovascular clinical trials and presents a definition to formally address this issue...
  20. ncbi Profile of patients with type 2 diabetes in France and Italy
    Faiez Zannad
    INSERM, CIC 9501 et U684, CHU Nancy, France
    J Hypertens 26:S3-6. 2008
    ..Greater adherence to therapeutic targets recommended in guidelines will ensure that greater proportions of patients attain these treatment goals thereby reducing diabetes-related morbidity and mortality...
  21. ncbi Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies
    Faiez Zannad
    Division of Hypertension and Preventive Cardiology, Department of Cardiology, Unité INSERM U 684, CIC INSERM CHU de Nancy, Hopital Jeanne d Arc, 54200 Dommartin Les Toul, France
    Fundam Clin Pharmacol 21:181-90. 2007
    ..Olmesartan efficacy was consistently at the highest end of the range of efficacy of ARBs studied...
  22. ncbi Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group
    F Zannad
    Centre d Investigation Clinique de Nancy, INSERM Centre Hospitalier Universitaire, Nancy, France
    J Hypertens 17:137-46. 1999
    ..To compare the therapeutic coverage and safety of amlodipine and perindopril in patients with mild to moderate hypertension (diastolic blood pressure > or = 90 mmHg and < or = 109 mmHg)...
  23. ncbi Left bundle branch block as a risk factor for progression to heart failure
    Faiez Zannad
    CIC INSERM CHU de Nancy, Hopital Jeanne d Arc, Dommartin les Toul, BP 303 54201 Toul Cedex, France
    Eur J Heart Fail 9:7-14. 2007
    ..It also aims to address the potential for future clinical therapies for this conduction disorder...
  24. ncbi A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone
    Natalia Lopez-Andres
    U, Faculty of Medicine, Institut National de la Sante et de la Recherche Medicale, Vandoeuvre les Nancy, France
    Am J Physiol Heart Circ Physiol 301:H2372-82. 2011
    ..CT-1-null mice were resistant to Aldo-induced LVH and fibrosis. These data suggest a key role for CT-1 in cardiac remodeling induced by Aldo independent of changes in blood pressure levels...
  25. ncbi Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial
    Chris Adamopoulos
    INSERM, Centre d Investigations Cliniques CIC Inserm CHU and U961, Hopital Jeanne d Arc, Toul 54200, France
    Eur J Heart Fail 11:1099-105. 2009
    ..To test the hypothesis that an earlier post-acute myocardial infarction (AMI) eplerenone initiation in patients with left ventricular systolic dysfunction (LVSD) and heart failure (HF) is associated with better long-term outcomes...
  26. ncbi Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
    Wafae Iraqi
    CHU de Nancy, Hopital Jeanne d Arc, Dommartin les Toul, France
    Circulation 119:2471-9. 2009
    ..Circulating biomarkers of collagen turnover provide a useful tool for the assessment of cardiac remodeling in patients with congestive heart failure and left ventricular systolic dysfunction after acute myocardial infarction...
  27. ncbi Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial
    Natalia Lopez-Andres
    INSERM U961, CIC Inserm CHU Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, Vandoeuvre les Nancy, France
    Eur J Heart Fail 14:74-81. 2012
    ..Our aim was to determine, in patients with heart failure (HF) and cardiac dyssynchrony, whether ECCM biomarkers are influenced by CRT and can predict cardiovascular outcomes and response to CRT...
  28. ncbi Association study of gene polymorphisms involved in vascular alterations in elderly hypertensives with subjective memory complaints
    Ghassan Watfa
    Nancy University Hospital and Inserm Clinical Investigation Center, CIC9501, Nancy, France
    Dement Geriatr Cogn Disord 30:440-8. 2010
    ..The aim of the present study was to identify genetic variants associated with the degree of cognitive impairment and the severity of WMH in the same study population, focusing on genes involved in vascular alterations...
  29. ncbi Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL
    Patrick Rossignol
    Institut National de la Sante et de la Recherche Medicale, Centre d Investigations Cliniques 9501, CHU Nancy, Vandoeuvre les Nancy, France
    Hypertension 60:339-46. 2012
    ..Such assessments should be prioritized for testing prevention strategies in end-stage renal disease...
  30. ncbi Pulse wave velocity assessment by external noninvasive devices and phase-contrast magnetic resonance imaging in the obese
    Laure Joly
    Centre de Geriatrie et Medecine Interne, CHU de Nancy, rue du Morvan, 54511 Vandoeuvre les Nancy, France
    Hypertension 54:421-6. 2009
    ..Our results indicate that, for body mass index values < or =35 kg m(-2), PWV measured externally with Complior or PulsePen validly reflect values obtained directly in the thoracic aorta through MRI...
  31. ncbi Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure
    Anca Radauceanu
    Centre d Investigation Clinique 9501, INSERM, Dommartin les Toul, France
    J Card Fail 14:467-74. 2008
    ..The relationship between markers of inflammation and of ECM remodeling, and their influence on functional status and outcomes has not been examined in a large cohort of CHF patients...
  32. ncbi Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol
    Anca Radauceanu
    Centre d Investigation Clinique CIC INSERM CHU, Hopital Jeanne d Arc, 54201 Dommartin les Toul, France
    Fundam Clin Pharmacol 18:483-91. 2004
    ..valsartan [DBP (P < 0.04), SBP (n.s.)]. Ankle edema were more often reported in amlodipine group. These results suggest a superior BP lowering and a longer duration of action with amlodipine compared with valsartan...
  33. ncbi [Official recommendations and guidelines for the management and reimbursement of severe hypertension as a chronic disease]
    Jean Marc Boivin
    Université Henri Poincaré et CIC Inserm de Nancy, Hopital Jeanne d Arc, F 54200 Dommartin les Toul, France
    Presse Med 38:652-60. 2009
    ..The ALD list should include severe hypertension as well as complicated and treatment-resistant hypertension, with the diagnosis documented by ambulatory or self blood pressure monitoring...
  34. ncbi Residual stress ischaemia is associated with blood markers of myocardial structural remodelling
    Anca Radauceanu
    Centre d Investigation Clinique CIC CHU INSERM, Nancy, France
    Eur J Heart Fail 9:370-6. 2007
    ..Long-term prognosis of coronary artery disease (CAD) patients is worsened when stress ischemia persists on treatment, but the relationship with adverse cardiac remodelling had never been investigated...
  35. ncbi Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints
    Anna Kearney-Schwartz
    Nancy University Hospital, Clinical Investigation Centre, J d Arc Hospital, Dommartin les Toul, France
    Stroke 40:1229-36. 2009
    ....
  36. ncbi Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
    Patrick Rossignol
    Centre d Investigations Cliniques INSERM CHU de Nancy, France
    Circulation 125:271-9. 2012
    ....
  37. ncbi Comprehensive MRI analysis of early cardiac and vascular remodeling in middle-aged patients with abdominal obesity
    Damien Mandry
    CHU Nancy, Department of Radiology, Nancy, France
    J Hypertens 30:567-73. 2012
    ....
  38. ncbi C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway
    Gaelle Bello
    INSERM, U684, Vandoeuvre les Nancy, F 54500 France
    Atherosclerosis 200:286-93. 2008
    ..CRP increases VEGF-A expression via a PI3-kinase and an extracellular-signal-regulated kinase (ERK) 1/2 dependent pathway. Our results suggest that CRP could play a role in the angiogenesis process via immune cells such as monocytes...
  39. ncbi Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes
    Francois Alla
    Epidemiology Department EA 3444, University Hospital, Nancy, France
    Eur J Heart Fail 8:147-53. 2006
    ..Our objective was to compare blood markers of collagen turnover among patients with CHF, patients with hypertension and type II diabetes (HD), and healthy individuals...
  40. ncbi Galectin-3 mediates aldosterone-induced vascular fibrosis
    Laurent Calvier
    INSERM, U961, Faculty of Medicine, Université de Lorraine, Vandoeuvre les Nancy, France
    Arterioscler Thromb Vasc Biol 33:67-75. 2013
    ..Galectin-3 (Gal-3), a β-galactoside-binding lectin, plays an important role in inflammation, fibrosis, and heart failure. We investigated here whether Gal-3 is involved in Aldo-induced vascular fibrosis...
  41. ncbi Sympathetic-leptin relationship in obesity: effect of weight loss
    Didier Quilliot
    centre d investigation clinique, INSERM CHU, Nancy, France
    Metabolism 57:555-62. 2008
    ..Our results imply therefore that the relationship between leptin and the autonomic nervous system is disturbed in normotensive obese subjects...
  42. ncbi Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study
    Michele Kessler
    Department of Nephrology, University Hospital of Nancy, Nancy, France
    Nephrol Dial Transplant 22:3573-9. 2007
    ..A risk prediction model was created from the FOSIDIAL trial to identify factors predictive of CVE and to evaluate the relative strength of known predictors when considered together in a multivariate model...
  43. ncbi Left bundle branch block and mortality in patients with acute heart failure syndrome: a substudy of the EFICA cohort
    Etienne Huvelle
    CIC INSEM CHU, Nancy, Hopital Jeanne d Arc, BP 90303, 54201 Toul Cedex, France
    Eur J Heart Fail 12:156-63. 2010
    ..We aimed to investigate the association of LBBB with short- and long-term outcome in patients discharged after a de novo episode of acute heart failure (AHF) or AHF complicating a mild CHF...
  44. ncbi Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy
    Anna Kearney-Schwartz
    Hopital Jeanne d Arc, CHU Nancy, Dommartin les Toul, F 54201, France
    Fundam Clin Pharmacol 21:387-96. 2007
    ..Other factors potentially contributing to rheology and arterial changes may be more critical in HT + DM patients and need further investigation...
  45. ncbi Can we prevent or treat renal dysfunction in chronic heart failure?
    Daniela Dobre
    INSERM, Center of Clinical Investigation 9501, University Hospital Nancy, Lorrain Institute of Heart and Vessels Louis Mathieu, 4, rue du Morvan, 54500 Vandoeuvre les Nancy, France
    Heart Fail Rev 17:283-90. 2012
    ..In conclusion, prevention of renal dysfunction is possible in CHF, but treatment is still under investigation. New studies are necessary to establish whether a specific algorithm may be used to prevent renal dysfunction in CHF patients...
  46. ncbi Epidemiology of acute heart failure syndromes
    Francois Alla
    Epidemiology, INSERM University Hospital, Nancy University, Nancy, France
    Heart Fail Rev 12:91-5. 2007
    ..Further epidemiological and clinical research is needed to improve our understanding of AHFS, thereby enhancing patient care...
  47. ncbi Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction
    Hugues Blangy
    Departement de Cardiologie, CHU de Nancy, Hopital de Brabois, rue du Morvan, 54511, Vandoeuvre les Nancy, France
    Europace 9:724-9. 2007
    ....
  48. ncbi Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure
    Faiez Zannad
    Department of Cardiology, Division of Heart Failure, Hypertension and Preventive Cardiolgy, and Centre d'Investigation Clinique CIC INSERM-CHU, University Henri Poincar, Nancy, France
    Heart Fail Rev 10:71-8. 2005
    ..Understanding various autocrine/paracrine mechanisms involved in extracellular matrix remodeling in heart failure represents a major challenge, essential for developing new cardioreparative and cardioprotective strategies...
  49. ncbi Initial infarct size predicts subsequent cardiac remodeling in the rat infarct model: an in vivo serial pinhole gated SPECT study
    Fatiha Maskali
    UHP INSERM U684, Faculty of Medicine, Nancy, France
    J Nucl Med 47:337-44. 2006
    ..The aim of this study was to assess this new imaging technique for predicting and quantifying variable LV remodeling from the rat infarct model...
  50. ncbi Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship
    F Zannad
    Centre d'Investigation Clinique INSERM-CHU, Centre Hospitalier Universitaire, Equipe d'Accueil EA 2403, , Nancy, France
    Hypertension 38:1227-32. 2001
    ....
  51. ncbi FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics
    Faiez Zannad
    Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, and Centre d Investigations Cliniques INSERM CHU, Toul, France
    Fundam Clin Pharmacol 16:353-60. 2002
    ..All patients were included by December 2000 and follow-up is ongoing. The last visit for the last patient is scheduled for 30 December 2002. We report here on the study design and the baseline characteristics of the study population...
  52. ncbi Influence of the recommendations on the implementation of home blood pressure measurement by French general practitioners: a 2004-2009 longitudinal survey
    Jean Marc Boivin
    Clinical Investigation Center Inserm CIC9501, Lorrain du Coeur et des Vaisseaux Louis Mathieu, Nancy, France
    J Hypertens 29:2105-15. 2011
    ....
  53. ncbi Biomarkers of extracellular matrix turnover
    Faiez Zannad
    Hopital Jeanne d Arc, Dommartin les Toul, France
    Heart Fail Clin 5:589-99. 2009
    ..ECCM biomarkers are clinically useful tools, particularly given the potential for cardioprotective and cardioreparative pharmacologic strategies...
  54. ncbi Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use
    Nathalie Thilly
    Service d épidémiologie et évaluation cliniques UPRES EA3444, CHU Nancy, Nancy, France
    J Eval Clin Pract 9:373-82. 2003
    ..This study aimed to evaluate the effect of developing and implementing Clinical Practice Guidelines (CPGs) on the quality of care given to patients receiving ACE inhibitors for systolic heart failure...
  55. ncbi [Angiotensin-converting enzyme inhibitors in congestive heart failure: clinical practice guidelines]
    Nathalie Thilly
    Service d Epidémiologie et Evaluation Cliniques UPRES EA1124, Hopital Marin, CHU Nancy, Nancy, France
    Therapie 58:341-9. 2003
    ..The drafting of the clinical practice guidelines is the first step in a quality improvement programme, initiated in 1999 in the cardiology wards of the region...
  56. ncbi Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial
    Daniela Dobre
    INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy, France
    Eur J Heart Fail 15:221-7. 2013
    ..We aimed to assess the association between statin therapy and clinical outcomes in the setting of acute HF with systolic dysfunction complicating acute MI...
  57. ncbi Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St
    Patrick Rossignol
    INSERM, Centre d Investigations Cliniques 9501, Nancy, France
    J Am Coll Cardiol 58:1958-66. 2011
    ....
  58. ncbi Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study
    Francois Alla
    Department of Epidemiology, University Hospital, Nancy, France
    Eur J Heart Fail 4:337-43. 2002
    ..The aim of this study was to determine the value of QoL score as a prognostic factor in a prospective cohort of patients with advanced chronic heart failure (CHF)...
  59. ncbi Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
    Faiez Zannad
    Centre d Investigation Clinique INSERM, CHU de Nancy, Hopital Jeanne d Arc, Toul, France
    Am Heart J 144:508-15. 2002
    ..In obese subjects, weight reduction regresses LV mass (LVM), regardless of blood pressure. Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss...
  60. ncbi Aldosterone and telomere length in white blood cells
    Athanase Benetos
    INSERM Unit 684, University of Nancy, 54511 Nancy les Vandoeuvre, France
    J Gerontol A Biol Sci Med Sci 60:1593-6. 2005
    ..The aim of the present study was, therefore, to examine the relationship between plasma aldosterone and telomere length in WBCs...
  61. ncbi Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers
    Pierre Y Marie
    Department of Nuclear Medicine and Cardiology, UPRES EA 3447, CHU Nancy Brabois, 54511 Vandoeuvre Cedex, France
    J Nucl Cardiol 10:361-8. 2003
    ..However, it is not known whether beta-blockers have the same beneficial prognostic effect when residual ischemia persists on treatment...
  62. ncbi Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers
    Pierre Yves Marie
    Department of Nuclear Medicine, UPRES EA 3447, Nancy, France
    J Am Coll Cardiol 43:353-9. 2004
    ..This study sought to identify determinants of the exercise rise in plasma levels of cardiac natriuretic peptides (NPs) in patients with coronary artery disease (CAD)...
  63. ncbi Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril
    Anca Radauceanu
    Centre d Investigation Clinique CIC, INSERM CHU de Nancy, France
    Fundam Clin Pharmacol 16:545-54. 2002
    ..Nevertheless, residual lowering of blood pressure at 48-h trough suggests that Tra had a longer duration of action than Qui...
  64. ncbi Environmental and genetic determinants of intima-media thickness of the carotid artery
    F Zannad
    Centre d Investigation Clinique INSERM CHU de Nancy, France
    Clin Exp Pharmacol Physiol 28:1007-10. 2001
    ..8. In women, none of the studied polymorphisms was associated with CIMT variation. 9. Our study gives new perspectives for understanding CIMT variability in healthy middle-aged subjects...
  65. ncbi Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators
    F Zannad
    Department of Cardiology, Centre d Investigation Clinique INSERM CHU, University Henri Poincare, Nancy, France
    Am Heart J 136:672-80. 1998
    ....
  66. ncbi Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine
    F Zannad
    Cardiology Department, centre d investigation clinique, INSERM CHU, Nancy, France
    J Am Coll Cardiol 33:734-42. 1999
    ..Characterize the incidence, clinical and etiologic features and outcomes of advanced congestive heart failure...
  67. ncbi Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance
    D Quilliot
    Service de Diabetologie, Maladies Métaboliques et de Nutrition, Hopital Jeanne d Arc, Centre Hospitalier Universitaire de Nancy, Nancy, France
    Int J Obes (Lond) 29:1321-8. 2005
    ....
  68. ncbi Effects of medical therapy on outcome assessment using exercise thallium-201 single photon emission computed tomography imaging: evidence of a protective effect of beta-blocking antianginal medications
    P Y Marie
    Department of Nuclear Medicine, UPRES EA 2403, CHU Nancy, France
    J Am Coll Cardiol 34:113-21. 1999
    ..The purpose of this study was to determine whether antianginal medications modify the prognostic significance of exercise single photon emission computed tomography (SPECT) ischemia...
  69. ncbi Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators
    F Zannad
    Centre d Investigation Clinique INSERM CHU, Laboratory of Biochemistry, Centre Hospitalier Universitaire, University Henri Poincare, Nancy, France
    Circulation 102:2700-6. 2000
    ..It has been suggested that spironolactone may decrease cardiac fibrosis. We investigated the interactions between serum markers of cardiac fibrosis and the effect of spironolactone on outcome in patients with CHF...
  70. ncbi Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study
    F Alla
    Department of Epidemiology and Cardiology, University Hospital, Nancy, France
    Am Heart J 139:895-904. 2000
    ..The clinical management of severe congestive heart failure (CHF) should be graded according to the prognosis of each individual patient. Our objective was to elaborate a prognostic rating system for severe CHF...
  71. ncbi Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function
    B Guerci
    Service de Diabetologie, Maladies Metaboliques et Maladies de la Nutrition, Hopital Jeanne d Arc, CHU de Nancy, B P 303, 54201 Toul Cedex
    Diabetes Metab 27:425-34. 2001
    ..Finally, recent reports indicate that an improved metabolic control in diabetic patients, whatever the treatment used, is associated with near normalization or restoration of normal endothelial function...
  72. ncbi Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus
    B Guerci
    Service de Diabetologie, Maladies Metaboliques et Maladies de la Nutrition, Hopital Jeanne d Arc, CHU de Nancy, B P 303, 54201 Toul, Cedex
    Diabetes Metab 27:436-47. 2001
    ..Finally, recent reports indicate that an improved metabolic control in diabetic patients, whatever the treatment used, is associated with near normalization or restoration of normal endothelial function...
  73. ncbi Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance
    D Quilliot
    centre d investigation clinique, INSERM CHU, Nancy, France
    Clin Auton Res 11:79-86. 2001
    ..Decreased HR and BP variability could partly account for the higher cardiovascular risk and incidence of sudden death in obese persons...
  74. ncbi Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group
    F Zannad
    centre d investigation clinique, INSERM CHU, Nancy, France
    J Hypertens 17:1023-32. 1999
    ....
  75. ncbi Impaired response of cardiac autonomic nervous system to glucose load in severe obesity
    Didier Quilliot
    centre d investigation clinique, France
    Metabolism 54:966-74. 2005
    ..We hypothesized that, as a consequence of insulin resistance, an inability of insulin to increase the sympathetic modulation of heart rate (HR) and blood pressure (BP) would be observed in normotensive obese patients...
  76. ncbi Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption
    Pascale Dewachter
    , Centre Hospitalier Universitaire, Nancy, France
    Anesthesiology 103:40-9. 2005
    ..This could explain rapid organ dysfunction and resuscitation difficulties...
  77. ncbi [Performance evaluation of a tool for institutional protocol quality assurance]
    Laura Zanetti
    Centre d'Investigation Clinique (CIC, INSERM-CHU, , Dommartin les Toul, France
    Therapie 60:527-37. 2005
    ..Initiation of quality assurance tools, such as the one used in this study, was associated with some spontaneous improvement, but did not improve the result significantly...
  78. ncbi Changes in first-pass interstitial kinetics of DTPA in myocardium submitted to low-flow ischemia
    Fatiha Maskali
    Department of Nuclear Medicine, Unité mixte UHP Inserm U684, and the Laboratory of Hematology and Physiology, Faculty of Pharmacy, University Henri Poincare, Nancy, France
    Invest Radiol 40:766-72. 2005
    ..This study aimed to determine the changes during ischemia in the myocardial first-pass kinetics of DTPA, an extracellular tracer that is currently used for assessing myocardial perfusion with magnetic resonance imaging (Magnevist)...
  79. ncbi Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists
    F Zannad
    Clinical Pharmacology and Cardiology Department, , Centre Hospitalier Universitaire, Nancy, France
    Am J Hypertens 9:633-43. 1996
    ..This may have important clinical implications...
  80. ncbi Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study)
    M Echemann
    , , CHU Nancy, France
    Eur J Heart Fail 4:647-54. 2002
    ....
  81. ncbi Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases
    Patrick Rossignol
    INSERM, Centre d Investigations Cliniques 9501, France
    Curr Opin Nephrol Hypertens 22:59-64. 2013
    ....
  82. ncbi C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes
    Didier Hanriot
    INSERM, U684, Nancy, France
    Thromb Haemost 99:558-69. 2008
    ..Among these novel anti-inflammatory effects, we show clearly that CRP activates the LXRalpha pathway...
  83. ncbi Genetics of intima-media thickness
    Faiez Zannad
    Department of Cardiovascular Disease, Division of Hypertension and Preventive Cardiology, Equipe d Accueil 3447, Clinical Investigation Center INSERM CHU, University Henri Poincare, Nancy, France
    Curr Opin Lipidol 14:191-200. 2003
    ..The aim of this paper is to review the most recent available data on the genetic determinants of carotid intima-media thickness...
  84. ncbi Effects of blood pressure control on radial artery diameter and compliance in hypertensive patients
    Y Khder
    Department of Clinical Pharmacology, INSERM-CHU, University Henri Poincare, Nancy, France
    Am J Hypertens 10:269-74. 1997
    ..The results of this cross-sectional study suggest that compliance abnormalities of the radial artery, but not internal diameter changes may be reversed by effective therapeutic control of blood pressure in arterial hypertension...
  85. ncbi Pharmacogenomics in cardiovascular clinical trials
    R Shah
    CIC INSERM-CHU, Hopital Jeanne d'Arc, 54200 Dommartin Les Toul, France
    Fundam Clin Pharmacol 18:705-8. 2004
    ..Physicians will need to understand the concept of genetic variability, its interactions with the environment (e.g. drug-drug or drug-disease interactions), and its implication for patient care...
  86. ncbi [Proposal of a tool for providing patients with the main results of clinical research studies]
    Camille Ducki
    Centre d'Investigation Clinique, , Dommartin les Toul, France
    Therapie 60:545-51. 2005
    ..CONCLUSION: After analysis of their answers, we worked out the bases of our tool. This tool is tested in an implementation phase...
  87. ncbi [Management, cost and mortality of a cohort of patients with advanced heart failure (the EPICAL study)]
    F Fagnani
    , , CHU Nancy, France
    Therapie 56:5-10. 2001
    ..These findings confirmed the major clinical and economic interest of any intervention that could lower the rate of readmissions in this group of patients...
  88. ncbi Acute heart failure syndromes: current state and framework for future research
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circulation 112:3958-68. 2005
  89. ncbi Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 112:3391-9. 2005
    ..Those with heart failure or impaired left ventricular left ventricular function after acute myocardial infarction have high complication and mortality rates. Little is known about outcomes with contemporary therapies in these patients...
  90. ncbi Public awareness of heart failure in Europe: first results from SHAPE
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 26:2413-21. 2005
    ..The extent of public awareness in Europe is not known...
  91. ncbi Angiotensin receptor blockers: therapeutic targets and cardiovascular protection
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octobre, Madrid, Spain, and Division of Internal Medicine, Ospedali Civili, University of Brescia, Italy
    Blood Press 14:196-209. 2005
    ..Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing...
  92. ncbi Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure
    Bertram Pitt
    University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    J Am Coll Cardiol 46:425-31. 2005
    ....
  93. ncbi Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ..The results of EVEREST will determine whether these effects translate into improved clinical outcomes...
  94. ncbi Trough-to-peak ratio, smoothness index and morning-to-evening ratio: why, which and when?
    Faiez Zannad
    J Hypertens 21:851-4. 2003
  95. ncbi Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study
    Willem Remme
    Sticares Foundation, Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 18:153-9. 2004
    ....
  96. ncbi Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    Douglas L Mann
    Winters Center for Heart Failure Research, Baylor College of Medicine and the Houston VA, Houston, Tex 77030, USA
    Circulation 109:1594-602. 2004
    ..Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure...
  97. ncbi Rationale, design and methods of the CASHMERE study
    Tabassome Simon
    Department of Pharmacology, Paris VI University, Saint Antoine University Hospital AP HP, Paris, France
    Fundam Clin Pharmacol 18:131-8. 2004
    ..The results are expected for 2007...
  98. ncbi Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study
    Bertram Pitt
    University of Michigan Health System, Ann Arbor, Mich, USA
    Circulation 108:1831-8. 2003
    ..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
  99. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
    ....
  100. ncbi Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  101. ncbi Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial
    Sheldon Tobe
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Clin Hypertens (Greenwich) 9:120-7. 2007
    ..In diabetic hypertensive patients, 20 mg/d quinapril plus 5 mg/d amlodipine besylate was a more effective BP-lowering strategy than monotherapy with 40 mg/d quinapril...